Puma Biotechnology | PBYI - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amgen USD 1.58B 354M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Exelixis USD 139.6M 16.58M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Incyte USD 328.1M 62.31M 2026-03
MacroGenics USD 7.94M 1.96M 2025-12
Moderna USD 173M 135M 2026-03
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Takeda JPY 292B 9.21B 2026-03
TG Therapeutics USD 73.14M 22.42M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03